Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 16th October 2018
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dopharma to acquire Boehringer Ingelheim production site
The move follows the presentation of Boehringer’s animal health strategic orientations.

Sale of Saint-Herblon site expected to complete in early 2019

Boehringer Ingelheim has announced the sale of its production site in Saint-Herblon, France, to Dutch company Dopharma.

First announced in October last year, the move follows the presentation of Boehringer’s animal health strategic orientations.

The group confirmed its strategy to focus on advanced and preventative healthcare; Saint-Herblon mainly produces generics and antibiotics for livestock.

Dopharma is an independent, family-owned company that develops, produces and distributes veterinary products for livestock.

Erick Lelouche, president of Boehringer Ingelheim Animal Health in France, said: “I am convinced that this project will offer a solid foundation for the future to the site and its employees. Indeed, we will collaborate with Dopharma Saint-Herblon that will produce some of our specialized products during the coming years.”

The sale is expected to complete by the end of the first quarter of 2019, after the legal and consultation process is finalised.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.